Virtuoso Epigenomics Platform: Revealing Biological Changes in Plasma

Traditional drug development processes are challenged by limited tissue availability and lack of tools that can capture tumor evolution and biology that is driven by non-genetic mechanisms. To address these challenges, ClearNote Health introduced the Virtuoso Epigenomics Platform, a groundbreaking whole genome sequencing and 5hmC enrichment solution designed to revolutionize translational research by revealing active disease biology to empower drug discovery and development.

The Virtuoso Platform represents a paradigm shift in drug development, offering non-invasive testing, longitudinal research capabilities, and individualized patient epigenomics to reveal critical biological changes in plasma. By leveraging these capabilities, the Virtuoso Platform accelerates drug development and advances precision medicine.

	Virtuoso utilizes the epigenetic marker 5hmC to deliver actionable insights into active disease biology. Through this information-rich epigenetic marker, Virtuoso enables the assessment of gene activation patterns and identification of tumor-relevant molecular signatures offering disease specific insights.
	Virtuoso uses whole genome sequencing with a proprietary 5hmC enrichment process. Unlike traditional DNA methylation approaches that rely on deep sequencing over targeted panels, Virtuoso delivers an unbiased genome-wide view into active biology, accelerating research and discovery.
	Virtuoso is a tumor-naive platform that allows detection of disease biology across cancer types and stages. With unparalleled versatility, the platform provides disease insights beyond tumor cells, from tumor microenvironment and immune cells, offering a holistic view into therapy response and clinical outcomes.

From Blood To Breakthrough

Integrated 5hmC Profile Analysis for Enhanced Clinical Insight